Abstract
Background:
Malignant melanotic nerve sheath tumors (MMNSTs) are rare Schwann cell–derived tumors. Previously classified as benign melanotic schwannomas, they were redefined as a potentially aggressive entity in the 2020 WHO classification of soft tissue tumors and later included in the 2021 WHO CNS classification. However, optimal therapeutic strategies remain under discussion.
Case presentation:
We present the case of a 46-year-old Caucasian male who underwent surgery for an intra- and extraspinal cervical mass lesion at the C4/5 level on the left side. Immunohistochemical analysis confirmed the diagnosis of MMNSTs. The patient initially presented with ataxia, left-sided weakness, and hemihypesthesia. Magnetic resonance imaging of the cervical spine revealed a left intra- and extraspinal homogeneous contrast-enhancing mass at the C4/C5 level. After the first intraspinal partial resection, the diagnosis of MMNST was established. Gross-total resection is highly recommended in nearly all cases in the literature, followed by adjuvant radiotherapy or chemotherapy in selected cases to prevent metastases, which occur in 15%–42% of cases. The patient postponed the second neurosurgical intervention and declined adjuvant radiotherapy. At 18 months after gross total resection, no recurrent tumor was detected by MRI.
Conclusion:
Given the limited epidemiological knowledge on MMNSTs, our study contributes to the literature by documenting a case of intra- and extraspinal, cervical MMNST without any of the previously known driver mutations or copy number changes. While the WHO 2021 classification designates these tumors as potentially malignant, our findings support existing reports that more benign courses can occur.
1 Introduction
Malignant melanotic nerve sheath tumor (MMNST) is a rare peripheral nerve sheath tumor showing both Schwann cell and melanocytic differentiation. Although melanotic schwannomas have historically been considered as rather benign lesions, the 2021 WHO classification of central nervous system tumors defines MMNSTs as a potentially aggressive entity (, ).
MMNSTs often harbor PRKAR1A mutations, particularly in patients with Carney complex (), an autosomal dominant syndrome associated with cardiac myxomas (), pigmented skin lesions, and endocrine tumors (). Loss of PRKAR1A expression has been proposed as a key molecular event in MMNST pathogenesis, leading to dysregulated cAMP signaling and tumorigenesis (). However, not all MMNST cases exhibit PRKAR1A loss, indicating potential alternative oncogenic mechanisms, such as aberrations in the MAPK or mTOR pathways (). Sporadic MMNSTs frequently retain PRKAR1A expression ().
Despite their classification as malignant, MMNSTs exhibit variable clinical behavior, ranging from indolent locally controlled disease to aggressive tumors with distant spread. Metastases have been reported, most commonly in the lungs (), liver (), and bones (). Due to this variability, there is no standardized treatment protocol, and management remains largely individualized. While gross total resection (GTR) is the preferred treatment (, ), the role of adjuvant radiotherapy and systemic therapy remains uncertain, particularly in cases with complete surgical removal and no high-risk histopathological features. Some reports suggest that radiotherapy may improve local control (, ), while others argue that it can be postponed in cases without aggressive histopathology ().
Our case presents a cervical intra- and extraspinal MMNST without PRKAR1A mutation or copy number changes, a finding rarely documented in the literature. Since the most recent WHO classification, 18 intraspinal MMNSTs have been reported, including four located in the cervical spine and one at the cervicothoracic junction. This rare occurrence, with its unique molecular profile and favorable clinical course, contributes to the ongoing discussion of which MMNST subtypes exhibit aggressive behavior and which cases may warrant adjuvant therapy.
2 Case presentation
A 46-year-old Caucasian male carpenter with a 6-week history of left-sided weakness and hemihypesthesia was admitted to the Department of Neurosurgery. Initial cranial imaging ruled out multiple sclerosis and stroke. Subsequent imaging revealed a contrast-enhancing intraspinal mass at the level of C4/C5, extending to the left side and encasing the left C5 nerve root up to the vertebral artery (Figure 1).
Figure 1
Clinical examination revealed adduction paresis of the fingers of the left hand (muscle strength grade 3/5), atrophy of the interosseous muscles, distally accentuated hypesthesia of the left upper extremity, spasticity of the left lower extremity, and an unsteady gait with a tendency to fall to the left. Routine laboratory parameters, including markers of infection and inflammation, were within normal limits.
The patient was very anxious and initially reluctant to undergo the proposed treatment. Only six weeks after the initial diagnosis he agreed to neurosurgical resection. Intraoperatively, the tumor was encapsulated by white, fibrous tissue, compressing the spinal cord and displacing it to the midline. Inside the capsule, black granular tissue triggered suspicion of melanoma, which was supported by the intraoperative frozen section analysis. Significant bleeding complicated the initial surgery. Due to persistent hemorrhage and the suspicion of malignancy, surgical resection was halted after intradural decompression of the spinal cord and partial lateral tumor removal.
Following surgery, the patient initially presented with persistent hypesthesia of the right arm, distal weakness of the left arm with a muscle strength grade of 4/5, and proximal weakness of the right arm with a strength grade of 3/5. Over the course of follow-up, a gradual improvement was observed. The abduction weakness in the right arm persisted with a strength grade of 3/5, while left arm flexion improved to 4/5. Hypesthesia in the right arm showed regression. Additionally, gait steadiness improved progressively.
Histologically, the tumor showed an epithelioid to spindle-shaped morphology with heavy melanotic pigmentation and moderate cellularity, arranged in short fascicles (Figure 2A). There were no signs of cellular atypia, mitoses or necrosis. There were no psammoma bodies.
Figure 2
The tumor tissue demonstrated broad immunohistochemical positivity for S-100, MelanA, and HMB45, as well as for Sox10 (Figures 2B,C). In the current case, PRKAR1A immunoexpression was retained (Figure 2D). Ki67 immunostaining showed a low proliferative index of approximately 3% (Figure 2E).
Furthermore, molecular mutation detection and gene fusion analysis were initiated to exclude other morphological mimics of melanocytic tumors (primary CNS melanocytoma and melanoma, metastatic cutaneous melanoma). While these targeted analyses provided relevant molecular information, whole-exome sequencing (WES) was unfortunately not available due to technical reasons.
DNA methylation profiling was performed on formalin-fixed, paraffin-embedded (FFPE) tissue from both the primary and recurrent tumor using the Illumina Infinium MethylationEPIC BeadChip array (850k). Raw data were normalized and quality-controlled using the ChAMP R package. 17849 differentially methylated positions (DMPs) between the tumor samples and conventional schwannoma controls (n = 20) were identified using the champ.DMP() function, which is based on the limma package to fit linear models across all CpG sites. Analyses were conducted on M-values (log₂-transformed beta values) The Benjamini–Hochberg procedure was applied to control the false discovery rate (FDR). DMPs with an adjusted p-value < 0.05 were considered statistically significant. Gene sets related to the MAPK and mTOR signaling pathways were retrieved from the Molecular Signatures Database (MSigDB) via the msigdbr R package. DMPs associated with MAPK and mTOR signaling pathways were extracted for Gene set enrichment analysis (GSEA) using the clusterProfiler package, based on log-fold changes aggregated at the gene level from DMP results.
Significant enrichment of genes involved in the MAPK signaling pathway was observed (e.g., MAP3K5, MAPK11, PDGFRB, RASGRF1). In contrast, no significant enrichment of genes involved in the mTOR signaling pathway was detected (Figure 3A). A heatmap of associated CpG sites using beta values revealed distinct methylation patterns compared to controls (Figure 3B). Immunohistochemical staining demonstrated partial Cyclin D1 expression, supporting functional activation of the MAPK pathway, whereas no mTOR staining was observed (Figures 2F,G), consistent with the epigenetic findings. It should be noted that heavy melanin pigmentation limited the interpretation of the staining. Therefore, based on these results alone, mTOR expression cannot be definitively excluded, and precise quantification of Cyclin D1-positive cells remains challenging.
Figure 3
Targeted next-generation sequencing (NGS) using a customized hybrid-capture panel covering all coding regions as well as selected intronic and promoter regions of 130 genes [as described by Sahm et al. ()] revealed no mutations in PRKAR1A, BRAF, NRAS, GNAQ, GNA11, KIT, TERT, or any other gene included in the panel.
Mutation detection and gene fusion analysis were performed using the customized panels QIASeq targeted DNA Panel for Solid Tumors (Qiagen) and QIAseq targeted RNAscan Panel (Qiagen). High-throughput sequencing was then performed on a MiSeq (Illumina) instrument, which revealed wild-type sequences for the BRAF, NRAS, KIT, TERT, GNAQ, and GNA11 genes. Additionally, genome-wide DNA methylation analysis was performed using the EPIC Illumina Human Methylation 850 (850k) array v1.0. The methylation profile of the tumor was compared with previously defined methylation classes using the publicly available database of the German Center for Cancer Research (DKFZ) () via www.molecularneuropathology.org. The brain tumor classifiers v11b.4 and v12.5 showed the highest score for the methylation class of malignant melanotic nerve sheath tumor in the primary tumor (score: 0.71) and the extraspinal tumor remnant (score: 0,99), which could be confirmed via unsupervised tSNE analysis using the DistSNE platform (Figure 4A) (). Copy number profiling revealed none of the changes reported in the literature (Figure 4B) (), and no copy number alteration was observed at the PRKAR1A locus.
Figure 4
Interestingly, the sarcoma classifier showed a match in the primary tumor for soft tissue clear cell sarcoma (Score: 0.96), but EWSR1/CREB1 or ATF1 gene fusion were excluded. Additionally, mutation analysis of PRKAR1A was performed using a customized enrichment/hybrid-capture-based panel of genes recurrently altered in brain tumors (). This analysis revealed no PRKAR1A mutation, thereby confirming the immunohistochemical result. For histopathological examination, the FFPE tissue was sent to the German reference center for soft tissue and bone tumors, where the diagnosis was confirmed.
This case represents an interesting molecular profile of an MMNST without PRKAR1A mutation, without any of the reported copy number changes, and without other previously known driver mutations.
3 Postoperative course
Complete resection followed by radiotherapy was recommended by the sarcoma board and the interdisciplinary neuro-oncology board. At the time of considering a second neurosurgical intervention, the patient had not yet been able to resume his profession as a painter. Although gait and postural stability had significantly improved after the initial surgery, he continued to experience sensory disturbances in the left shoulder radiating to both thumbs and index fingers, more pronounced on the left side. Additionally, he reported paresthesia predominantly affecting the right thumb and persistent neck pain exacerbated by forward bending. Although no paresis of the upper extremities was present, he still suffered from exertional weakness. Only after careful consideration of the persistent symptoms and the recommendations did the patient agree to a second neurosurgical intervention, which was performed five months after the initial partial resection.
This time, according to the view of the operative microscope and confirmed by early postoperative MRI (Figure 1), complete resection was achieved. The paresis further improved, and the patient reported no complaints. During follow-up, the patient described paresthesia on the left side and noted similar sensations extending to his right thumb. His gait became steady.
Upon clinical reassessment based on the histologic diagnosis, the patient exhibited no clinical features indicative of Carney complex, such as pigmented skin lesions, cardiac myxoma, or endocrine dysfunction. Additionally, there was no family history of Carney complex or related syndromes.
Subsequently, the patient agreed to undergo oncologic and radiotherapeutic counseling but continued to decline radiotherapy. His decision was influenced by the significant improvement in symptoms and the absence of recurrence on MRI. The most recent MRI, performed 18 months after the initial surgery, showed no evidence of recurrent disease. At the two-year follow-up, the patient reported only mild, persistent paresthesia.
4 Discussion
We describe a rare case of a cervical MMNST with intra- and extraspinal extension, absence of PRKAR1A mutation, absence of detectable copy number changes, and a benign clinical course without adjuvant therapy. The patient remained recurrence-free for 24 months after gross total resection, suggesting that not all MMNSTs exhibit aggressive behavior. These findings are in line with recent reports of sporadic MMNSTs retaining PRKAR1A expression and lacking metastatic potential.
Malignant melanotic nerve sheath tumors account for less than 1% of all primary peripheral nerve sheath tumors and most often arise from the spinal nerves or visceral autonomic nerves (–). There have been documented cases in various anatomical locations, including the stomach, bone, soft tissue, heart, liver, choroid, and skin (, ).
MMNST has historically been regarded as an atypical variant of schwannoma and, due to its pigmentation, has been referred to as melanotic schwannoma (). The first documented case dates back to 1932, and in 1975 the close relationship of these tumors to the sympathetic chain, as well as their metastatic potential, was described (–).
In some series, over 50% of patients with MMNSTs have evidence of Carney complex, an autosomal dominant, occasionally familial multiple neoplasia syndrome (). However, other studies have reported an association with Carney complex in less than 5% of affected patients (, –). Some cases occur sporadically with an unknown etiology (). MMNSTs associated with Carney complex more frequently display psammomatous morphology (). A few reported cases have shown an association with neurofibromatosis (). Importantly, the patient in our study did not exhibit any clinical features of Carney complex or neurofibromatosis. Psammomatous MMNSTs have more often been reported in association with Carney complex (, ), and PRKAR1A alterations are common in melanotic schwannoma (). Nevertheless, both psammomatous and non-psammomatous cases may variably harbor these alterations, and clinical behavior remains heterogeneous (). Our case, which displayed neither psammomatous features nor PRKAR1A loss, aligns with these latter reports. In such cases, alternative oncogenic pathways such as mTOR and MAPK activation must be considered. These findings underscore the heterogeneity of MMNSTs and emphasize the need for detailed molecular studies to define treatment strategies more precisely.
The average age at diagnosis of MMNST is 41 years, with a reported range of 11–81 years, which corresponds well to our patient (46 years) (). However, some sources suggest a mean age of 38 years (, ). It is important to note that there is no gender or ethnic predilection (, ).
Table 1 summarizes cases identified in PubMed using the search terms ‘‘MMNST’’ and ‘‘malignant melanotic nerve sheath tumor’’ that were published after the 2021 WHO CNS tumor classification, in which MMNST was designated a potentially aggressive condition. According to the cases summarized in Table 1, the average patient age is 42.9 years (range, 7–79 years). Sixteen patients were female and twelve male. Eighteen tumors were located in the spine, including four in the cervical region and one at the cervicothoracic junction.
Table 1
| Authors | Intraspinal | Extraspinal | Year | Sex | Age (years) | Radiotherapy | PFS (months) | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| Yeom et al. () | T11–T12 | 2022 | F | 58 | No | n.a. | n.a. | |
| T11 | 2022 | M | 72 | No (biopsy only) | 36a | 36 | ||
| Terry et al. () | S2 | 2022 | F | 48 | Yes (59.4 Gy/33 fr) | 5 | 18 | |
| Hall et al. () | S1 | 2022 | F | 18 | Yes (40 Gy/f fr) | 30a | 30 | |
| Yan et al. () | S2 | 2022 | M | 33 | Yes (56 Gy) | 15a | 15 | |
| Buckley et al. (47) | Pararenal | 2022 | M | 70 | No | n.a. | n.a. | |
| Zlatarov et al. () | Adrenal gland | 2022 | F | 11 | No | 2a | 2 | |
| Lin et al. (48) | Para-aortic area | 2022 | F | 59 | Yes | 11a | 11 | |
| Jackson et al. (49) | Presacral and Pleural effusion | 2022 | F | 60 | Yes | n.a. | 8 | |
| Grandmougin et al. (50) | C2–C3 | 2023 | F | 31 | No | n.a. | n.a. | |
| Shui et al. (51) | L5–S1 | 2022 | F | 21 | Yes (after leptomeningeal spread) | 4 | n.a. | |
| Li et al. (52) | Parotid gland | 2023 | M | 52 | No | n.a. | n.a. | |
| Bonomo et al. () | C5–C6 | 2023 | F | 28 | No | 12 | 12 | |
| Rachao et al. (53) | Cavernous sinus | 2023 | M | 42 | Yes (54 Gy/30fr) | n.a. | n.a. | |
| Xiang et al. (54) | T6–T7 | 2023 | M | 60 | No | n.a. | n.a. | |
| McCann et al. (55) | T8–T11 | 2023 | M | 40 | Planned | 3a | 3 | |
| Chen P et al. () | Retroperitoneal | 2024 | F | 47 | No | 36 | 36 | |
| Kageyama (56) | T9–T10 | 2024 | M | 79 | No | 12 | 12 | |
| Chen S et al. (57) | C7–T1 | 2024 | F | 27 | No | 7 | n.a. | |
| Agostini et al. (58) | Meckel's cave | 2024 | F | 31 | Planned | n.a. | n.a. | |
| Franca et al. (59) | C4–C5 | 2024 | F | 50 | Yes | 1 | 12 | |
| Kallen et al. (60) | Retroperitoneal | 2024 | F | 38 | No | 9 | 13 | |
| Okal et al. (61) | L5–S2 | 2024 | M | 7 | Yes (31fr) | 12a | 12 | |
| Chong et al. (62) | S1–S3 | 2024 | M | 46 | No | 1 | 5 | |
| Sun et al. (63) | L5–S1 | 2024 | F | 55 | Yes | 12a | 12 | |
| Madesh et al. (64) | Posterior fossa | 2025 | F | 42 | No | n.a. | n.a. | |
| Haq et al. (65) | L5–S2 | 2025 | M | 30 | No | 12a | 12 | |
| Present case | C4–C5 | 2025 | M | 46 | No | 24 | 24 | |
| Summary (n = 28) | n = 18 | n = 10 | 16F/12M | Mean 42.9 | 10 Yeas/16 No /2 Planned | Mean 12.8b | Mean 15.2b |
Recently published MMNST cases since the 2021 WHO CNS classification.
PFS (progression-free survival), n.a. (not available), fr (fractions).
No progression at last follow-up (censored PFS).
PFS (n = 19) and follow-up (n = 18) were calculated only from cases with available data.
Radiologically, intramedullary melanotic neoplasms exhibit hyperintensity on T1-weighted MRI and hypointensity on T2-weighted MRI due to the paramagnetic effect of melanin. Extramedullary neoplasms are often confused with meningiomas, dermoids, or schwannomas (). FDG PET/CT can help in distinguishing between benign and malignant lesions and in assessing treatment response in MMNSTs ().
Follow-up information in the available literature is heterogeneous and often limited. Reviewing publications that also included cases reported before the 2021 WHO classification revealed equivocal treatment results. Torres-Mora et al. reported a mean follow-up of 56 months (range, 1–300 months) in 26 patients, with frequent recurrences and metastases (). Khoo et al. provided only short-term follow-up of up to 12 months in four patients (). Kwok et al. described 12 patients with a mean follow-up of 4.8 years (range, 1.3–10.2 years), of whom half remained disease-free, while others developed recurrence or died of disease (). The most recent large series by Ghaith et al. summarized 71 patients and found recurrence, metastasis, and mortality rates of 42%, 27%, and 26%, respectively (). Collectively, these data illustrate that both early and late events occur, underscoring the necessity of long-term surveillance in MMNST. To date, apart from increased mitotic activity, no specific morphological features that reliably predict malignant vs. benign behavior have been identified.
Given the scarcity of reported cases, there are currently no established guidelines for the management of this tumor. Nevertheless, gross-total resection is recommended to minimize the risk of recurrence (–). Additionally, it is advisable to monitor patients in the outpatient clinic, including regular lung assessments, as the lungs are the most common site of metastasis (, ). Radiotherapy following subtotal or gross-total resection is strongly recommended ().
However, our patient continues to decline radiation therapy. His case underscores the heterogeneity of MMNSTs, as some tumors may follow a more indolent course. Given the absence of recurrence up to now, 24 months postoperatively, it remains uncertain in which cases immediate adjuvant therapy is needed. Regular long-term follow-up is crucial to confirm the durability of this favorable outcome.
5 Conclusion
Given the limited epidemiological knowledge about malignant melanotic nerve sheath tumors (MMNSTs), our study contributes to the literature by documenting a cervical intra- and extraspinal MMNST without previously described driver mutations or copy number changes. While the WHO 2021 classification designates these tumors as potentially malignant, our findings support existing reports that some cases may follow a more benign course. This case illustrates that predicting biological behavior can be challenging, even in the presence of a defined WHO classification. It is encouraging that the patient has experienced a favorable follow-up period after resection without irradiation or chemotherapy.
Statements
Data availability statement
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.
Ethics statement
Ethical approval was not required for this single case report in accordance with local institutional guidelines. Written informed consent was obtained from the patient for participation and for the publication of any potentially identifiable data or images.
Author contributions
AG: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. JW: Writing – review & editing. EG: Supervision, Writing – review & editing. MB: Writing – original draft, Writing – review & editing. PK: Writing – review & editing. UN: Conceptualization, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
We thank the patient for permitting us to use his data to complete this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2025.1618362/full#supplementary-material
References
1.
ChoiJHRoJY. The 2020 who classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol. (2021) 28(1):44–58. 10.1097/pap.0000000000000284
2.
LouisDNPerryAWesselingPBratDJCreeIAFigarella-BrangerDet alThe 2021 who classification of tumors of the central nervous system: a summary. Neuro Oncol. (2021) 23(8):1231–51. 10.1093/neuonc/noab106
3.
TerryMWakemanKWilliamsBJMillerDMSakMAbdullaevZet alMalignant melanotic nerve sheath tumor with Prkar1a, Kmt2c, and gnaq mutations. Free Neuropathol. (2022) 3:21. 10.17879/freeneuropathology-2022-3864
4.
ZhengHKangHQiuYXieLWuJLaiPet alNovel Prkar1a mutation in carney complex: a case report and literature review. Front Endocrinol (Lausanne). (2024) 15:1384956. 10.3389/fendo.2024.1384956
5.
VeugelersMWilkesDBurtonKMcDermottDASongYGoldsteinMMet alComparative Prkar1a genotype-phenotype analyses in humans with carney complex and Prkar1a haploinsufficient mice. Proc Natl Acad Sci USA. (2004) 101(39):14222–7. 10.1073/pnas.0405535101
6.
RahrmannEPWatsonALKengVWChoiKMoriarityBSBeckmannDAet alForward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. (2013) 45(7):756–66. 10.1038/ng.2641
7.
BensonJCMaraisMDFlaniganPMBydonMGianniniCSpinnerRJet alMalignant melanotic nerve sheath tumor. AJNR Am J Neuroradiol. (2022) 43(12):1696–9. 10.3174/ajnr.A7691
8.
TakatoriNHiyamaASakaiDKatohHSatoMWatanabeM. A rare case of intraspinal psammomatous melanotic schwannoma: a case report. Spine Surg Relat Res. (2020) 4(1):91–4. 10.22603/ssrr.2019-0034
9.
AzabMAMostafaHAAtallahO. Fdg-Pet/Ct avid uptake of a biopsy-proven aggressive melanotic schwannoma of the S2 spinal nerve root. World J Nucl Med. (2025) 24(1):71–4. 10.1055/s-0044-1791694
10.
AcemIMartinEvan HoudtWJvan de SandeMAJGrünhagenDJVerhoefCet alThe association of metastasis pattern and management of metastatic disease with oncological outcomes in patients with malignant peripheral nerve sheath tumors: a multicenter cohort study. Cancers (Basel). (2021) 13(20):5115. 10.3390/cancers13205115
11.
González-MuñozTKimARatnerNPeinadoH. The need for new treatments targeting mpnst: the potential of strategies combining mek inhibitors with antiangiogenic agents. Clin Cancer Res. (2022) 28(15):3185–95. 10.1158/1078-0432.Ccr-21-3760
12.
BradfordDKimA. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol. (2015) 16(3):328. 10.1007/s11864-015-0328-6
13.
RoohaniSClaßenNMEhretFJaroschADziodzioTFlörckenAet alThe role of radiotherapy in the management of malignant peripheral nerve sheath tumors: a single-center retrospective cohort study. J Cancer Res Clin Oncol. (2023) 149(20):17739–47. 10.1007/s00432-023-05449-9
14.
BishopAJZagarsGKTorresKEBirdJEFeigBWGuadagnoloBA. Malignant peripheral nerve sheath tumors: a single institution’s experience using combined surgery and radiation therapy. Am J Clin Oncol. (2018) 41(5):465–70. 10.1097/coc.0000000000000303
15.
KahnJGillespieATsokosMOndosJDombiECamphausenKet alRadiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. (2014) 4:324. 10.3389/fonc.2014.00324
16.
SahmFSchrimpfDJonesDTMeyerJKratzAReussDet alNext-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. (2016) 131(6):903–10. 10.1007/s00401-015-1519-8
17.
CapperDJonesDTWSillMHovestadtVSchrimpfDSturmDet alDNA methylation-based classification of central nervous system tumours. Nature. (2018) 555(7697):469–74. 10.1038/nature26000
18.
SchmidKSehringJNémethAHarterPNWeberKJVengadeswaranAet alDistsne: distributed computing and online visualization of DNA methylation-based central nervous system tumor classification. Brain Pathol. (2024) 34(3):e13228. 10.1111/bpa.13228
19.
WangLZehirASadowskaJZhouNRosenblumMBusamKet alConsistent copy number changes and recurrent Prkar1a mutations distinguish melanotic schwannomas from melanomas: snp-array and next generation sequencing analysis. Genes Chromosomes Cancer. (2015) 54(8):463–71. 10.1002/gcc.22254
20.
AlexievBAChouPMJenningsLJ. Pathology of melanotic schwannoma. Arch Pathol Lab Med. (2018) 142(12):1517–23. 10.5858/arpa.2017-0162-RA
21.
BonomoGGansAMazzapicchiERubiuEAlimontiPEoliMet alSporadic spinal psammomatous malignant melanotic nerve sheath tumor: a case report and literature review. Front Oncol. (2023) 13:1100532. 10.3389/fonc.2023.1100532
22.
BrierleyJDAsamuraHVan EyckenERousB, editors. Bone and soft tissue tumours. In: TNM Atlas. Hoboken, NJ: Wiley-Blackwell (2021). p. 209–25.
23.
CohenJNYehILeBoitPE. Melanotic schwannoma of the vulva: a case report and review of the literature. Am J Dermatopathol. (2020) 42(1):46–51. 10.1097/dad.0000000000001482
24.
HodsonJJ. An intra-osseous tumour combination of biological importance—invasion of a melanotic schwannoma by an adamantinoma. J Pathol Bacteriol. (1961) 82(2):257–66. 10.1002/path.1700820203
25.
MillarWG. A malignant melanotic tumour of ganglion cells arising from a thoracic sympathetic ganglion. J Pathol Bacteriol. (1932) 35(3):351–7. 10.1002/path.1700350305
26.
FuYSKayeGILattesR. Primary malignant melanocytic tumors of the sympathetic ganglia, with an ultrastructural study of one. Cancer. (1975) 36(6):2029–41. 10.1002/cncr.2820360917
27.
CarneyJA. Psammomatous melanotic schwannoma. A distinctive. Heritable tumor with special associations, including cardiac myxoma and the cushing syndrome. Am J Surg Pathol. (1990) 14(3):206–22. 10.1097/00000478-199003000-00002
28.
Vallat-DecouvelaereAVWassefMLotGCatalaMMoussalamMCaruelNet alSpinal melanotic schwannoma: a tumour with poor prognosis. Histopathology. (1999) 35(6):558–66. 10.1046/j.1365-2559.1999.00786.x
29.
Torres-MoraJDrySLiXBinderSAminMFolpeAL. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of “melanotic schwannoma”. Am J Surg Pathol. (2014) 38(1):94–105. 10.1097/PAS.0b013e3182a0a150
30.
ZhangHYYangGHChenHJWeiBKeQGuoHet alClinicopathological, immunohistochemical, and ultrastructural study of 13 cases of melanotic schwannoma. Chin Med J (Engl. (2005) 118(17):1451–61.
31.
ChenPChengJZhangL. Rare giant retroperitoneal melanotic schwannoma: a case report and literature review. Front Oncol. (2024) 14:1448112. 10.3389/fonc.2024.1448112
32.
ShieldsLBGlassmanSDRaqueGHShieldsCB. Malignant psammomatous melanotic schwannoma of the spine: a component of carney complex. Surg Neurol Int. (2011) 2:136. 10.4103/2152-7806.85609
33.
ZlatarovADrenakovaPMihaylovSZgurovaNPetkovaLIvanovKD. Malignant psammomatous melanotic schwannoma mimicking adrenal cyst: case report. Ann Pediatr Surg. (2022) 18(1):51. 10.1186/s43159-022-00189-w
34.
RodriguezFJFolpeALGianniniCPerryA. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. (2012) 123(3):295–319. 10.1007/s00401-012-0954-z
35.
AlamerATampieriD. Brain and spine melanotic schwannoma: a rare occurrence and diagnostic dilemma. Neuroradiol J. (2019) 32(5):335–43. 10.1177/1971400919849819
36.
ShenXZWangWLuoZY. 18f-Fdg Pet/ct imaging for aggressive melanotic schwannoma of the L3 spinal root: a case report. Medicine (Baltimore). (2021) 100(8):e24803. 10.1097/md.0000000000024803
37.
KhooMPressneyIHargunaniRTiraboscoR. Melanotic schwannoma: an 11-year case series. Skeletal Radiol. (2016) 45(1):29–34. 10.1007/s00256-015-2256-8
38.
KwokHHameedMHwangS. Magnetic resonance imaging features and clinical course of malignant melanotic nerve sheath tumors: single institution experience over two decades. Skeletal Radiol. (2023) 52(2):205–14. 10.1007/s00256-022-04171-w
39.
GhaithAKJohnsonSEEl-HajjVGAkinduroOOGhanemMDe BiaseGet alSurgical management of malignant melanotic nerve sheath tumors: an institutional experience and systematic review of the literature. J Neurosurg Spine. (2024) 40(1):28–37. 10.3171/2023.8.Spine23427
40.
MeesSTSpiekerTEltzeEBrockmannJSenningerNBruewerM. Intrathoracic psammomatous melanotic schwannoma associated with the carney complex. Ann Thorac Surg. (2008) 86(2):657–60. 10.1016/j.athoracsur.2008.02.007
41.
ErUKazanciAEyriparmakTYigitkanliKSenveliE. Melanotic schwannoma. J Clin Neurosci. (2007) 14(7):676–8. 10.1016/j.jocn.2006.03.010
42.
HooverJMBledsoeJMGianniniCKraussWE. Intramedullary melanotic schwannoma. Rare Tumors. (2012) 4(1):7–10. 10.4081/rt.2012.e3
43.
WatsonJCStratakisCABryant-GreenwoodPKKochCAKirschnerLSNguyenTet alNeurosurgical implications of carney complex. J Neurosurg. (2000) 92(3):413–8. 10.3171/jns.2000.92.3.0413
44.
YeomJASongYSLeeISHanIHChoiKU. Malignant melanotic nerve sheath tumors in the spinal canal of psammomatous and non-psammomatous type: two case reports. World J Clin Cases. (2022) 10(24):8735–41. 10.12998/wjcc.v10.i24.8735
45.
HallJCChangSDWilsonTJGanjooKNTolandAVogelHet alPost-operative stereotactic radiosurgery of malignant melanotic schwannoma. Cureus. (2022) 14(3):e22849. 10.7759/cureus.22849
46.
YanXWangKLinNHuangXFuYYeZ. A rare case of melanotic schwannoma occurred intraosseous of Sacrum: a literature review. Orthop Surg. (2023) 15(2):655–62. 10.1111/os.13606
47.
BuckleyBDelaneyFAirdJJBolsterF. Pararenal malignant melanotic nerve sheath tumour: a rare tumour in an unfamiliar location. BMJ Case Rep. (2022) 15(8):e252107. 10.1136/bcr-2022-252107
48.
LinK-YChenLHungS-WHungS-CYangC-KChenC-Jet alA para-aortic malignant melanotic nerve sheath tumor mimicking a gastrointestinal stromal tumor: a rare case report and review of literature. BMC Surg. (2022) 22(1):293. 10.1186/s12893-022-01727-4
49.
JacksonCLinosKLiuX. Malignant melanotic nerve sheath tumor in pleural effusion: deceitful cytology with significant repercussions. Diagn Cytopathol. (2022) 50(3):E76–80. 10.1002/dc.24895
50.
GrandmouginDMoussuTHubertMPerinBHuberADelolmeMCet alRecurrent biatrial myxomas in carney Complex with a spinal melanotic schwannoma: advocacy for a rigorous multidisciplinary follow-up. Case Rep Cardiol. (2023) 2023:7896180. 10.1155/2023/7896180
51.
ShuiCDaveyLScholsemM. Leptomeningeal dissemination of a malignant melanotic nerve sheath tumor: a case report and review of the literature. Surg Neurol Int. (2022) 13:59. 10.25259/sni_31_2022
52.
LiZNiuY. Malignant melanotic nerve sheath tumor of the parotid gland: a case report and literature review. Ear Nose Throat J. (2025) 104(1_suppl):339s–44. 10.1177/01455613221145803
53.
RachãoAFerroMRoqueRCamposARPimentelJ. A case of trigeminal malignant melanotic nerve sheath tumor in the wide Spectrum of melanotic and nerve sheath tumors. Neuropathology. (2023) 43(4):345–8. 10.1111/neup.12891
54.
XiangZFengMGaoQShangH. Malignant thoracic intraspinal melanotic schwannoma. Asian J Surg. (2023) 46(11):4794–5. 10.1016/j.asjsur.2023.05.096
55.
McCannMMHainJD. Intramedullary melanotic schwannoma: a rare presentation of a rare tumor. Illustrative Case. J Neurosurg Case Lessons. (2023) 5(7):CASE22391. 10.3171/case22391
56.
KageyamaH. Spinal malignant melanotic nerve sheath tumor with atypical magnetic resonance imaging findings: a case report. Surg Neurol Int. (2024) 15:250. 10.25259/sni_447_2024
57.
ChenSWeiY. Malignant melanotic schwannoma of the cervical spinal cord: a case report. BMC Neurol. (2024) 24(1):181. 10.1186/s12883-024-03686-0
58.
AgostiniLRychenJVigoVLjubimovVAFernandez-MirandaJC. Trigeminal malignant melanotic nerve sheath tumor: 3-dimensional operative video. Oper Neurosurg (Hagerstown). (2024). 10.1227/ons.0000000000001449
59.
FrancaRADi CrescenzoRMUggaLDella MonicaRD'AvellaE. The “pigmented Side” of nerve sheaths: malignant melanotic nerve sheath tumor. Int J Surg Pathol. (2024) 33(4):1068–81. 10.1177/10668969241295689
60.
KallenMEKokaRHausnerPFBenyounesA. Malignant melanotic nerve sheath tumor - a pitfall in the diagnosis of schwannoma. Int J Surg Pathol. (2024) 33(3):670–2. 10.1177/10668969241271902
61.
OkalFMHafizBEAlassiriAAlamriZAlshayaW. Interosseous malignant melanotic nerve sheath tumor of the Sacrum treated with an innovative reconstruction technique. Cureus. (2024) 16(7):e64820. 10.7759/cureus.64820
62.
ChongJKDubeyNKLoWC. Intradural melanotic schwannoma of the sacral spine: an illustrated case report of diagnostic conundrum. Reports (MDPI). (2024) 7(3):56. 10.3390/reports7030056
63.
SunZWangXPangX. Malignant melanotic schwannoma: a case report and literature review. Asian J Surg. (2024) 47(1):640–1. 10.1016/j.asjsur.2023.09.145
64.
MadeshMPericherlaSChindhaloreS. Intracranial malignant melanotic nerve sheath tumor: illustrative case. J Neurosurg Case Lessons. (2025) 9(15):CASE24473. 10.3171/case24473
65.
HaqNUKhanGAHaiderSFareedANooriSQayyumSN. Extradural malignant melanotic nerve sheath tumor of the lumbosacral spine: a diagnostic and surgical challenge. Ann Med Surg (Lond). (2025) 87(6):3940–4. 10.1097/ms9.0000000000003327
Summary
Keywords
malignant melanotic nerve sheath tumor (MMNST), cervical nerve root, melanotic schwannoma, psammomatous melanotic schwannoma, case report
Citation
Guranda A, Wach J, Güresir E, Braune M, Kuzman P and Nestler U (2025) Cervical Malignant Melanotic Nerve Sheath Tumor with retained PRKAR1A expression and a clinically benign course: a case report and review of the literature. Front. Surg. 12:1618362. doi: 10.3389/fsurg.2025.1618362
Received
25 April 2025
Accepted
28 August 2025
Published
15 September 2025
Volume
12 - 2025
Edited by
Rafael De La Garza Ramos, Albert Einstein College of Medicine, United States
Reviewed by
Marica Eoli, IRCCS Carlo Besta Neurological Institute Foundation, Italy
Hajnalka Rajnai, Semmelweis University, Hungary
Zhenhua Li, Brigham and Women's Hospital and Harvard Medical School, United States
Updates
Copyright
© 2025 Guranda, Wach, Güresir, Braune, Kuzman and Nestler.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alexandru Guranda alexandru.guranda@medizin.uni-leipzig.de
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.